Skip to main
ARVN

Arvinas Inc (ARVN) Stock Forecast & Price Target

Arvinas Inc (ARVN) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 35%
Hold 29%
Sell 0%
Strong Sell 6%

Bulls say

Arvinas Inc demonstrates a strong positive outlook primarily due to its increasing enterprise value, which has risen from $627 million to $959 million, reflecting heightened market confidence in its innovative pipeline. The valuations of key drug candidates, including ARV-102, ARV-806, and ARV-393, have significantly increased, indicating a positive progression in their development phases and potential commercial success. Additionally, the favorable safety profiles of their protein degradation therapies, evidenced by clinical data such as the 7% AST increase among patients taking ASP3082, lend further credence to the company's promising future in addressing critical healthcare needs.

Bears say

Arvinas Inc faces a negative outlook due to several concerning financial metrics and clinical developments. The projected revenue for its product candidate vepdegestrant has significantly decreased to $296.9 million by 2035, down from a previous estimate of $641.2 million, suggesting reduced market potential stemming from unfavorable economic conditions and limited penetration in key cancer markets. Additionally, the company's challenges in accessing capital could restrict its operational capabilities, impacting the timeline to achieve profitability and sustainable cash flow generation, further compounded by safety concerns arising from adverse effects in ongoing clinical trials.

Arvinas Inc (ARVN) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 35% recommend Buy, 29% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arvinas Inc (ARVN) Forecast

Analysts have given Arvinas Inc (ARVN) a Buy based on their latest research and market trends.

According to 17 analysts, Arvinas Inc (ARVN) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arvinas Inc (ARVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.